Information about patients' age, sex, ASA grade, burden of general morbidities (which was quantified using the Charlson co-morbidity score [ 18]), BMI, indication for and the nature of the procedure undertaken, and Mallampati [ 19] and Cormack-Lehane direct laryngoscopy grades [ 20] were recorded.
Therapeutic decision is mostly conditioned by patient's characteristics, stage, histologic grade, tumor burden, and risk-predicting factors.
The participants were asked to grade the burden of problems into "no, never", "yes, sometimes", "yes, many times" and "frequently".
We also sought to describe the proportion of the low grade disease burden that can be prevented by vaccination against HPV types 6, 11, 16, and 18.
YKL-40 levels seem to be related to tumor grade and burden, short recurrence-free interval and short disease-free and overall survival [ 11].
Finally, it was agreed that focal treatment could be used for multifocal disease, secondary lesions ≤5 mm of Gleason 3 + 3 could be left untreated, and a reduction of grade or burden of disease within the treated area reflects treatment success.
Andrew Rigie, executive vice president of the New York City chapter of the New York State Restaurant Association, said that the revised system of waiving fines for establishments with an initial A grade still burdens those restaurants that earn an A through the appeal process.
It uses tumour size, grade and nodal burden to classify patients into groups as good, moderate and poor prognosis, with NPI <3.4, 3.4 5.4 and >5.4, respectively.
The immunohistochemical (IHC) 4+C score is a prognostic tool based on quantitative values of four standard laboratory assays (ER, PR, HER2 and Ki67), and the clinicopathologic parameters of tumour grade, size, nodal burden, patient age, and treatment with AI or tamoxifen (hence IHC4+clinical (IHC4+C) score) (Cuzick et al, 2011).
These results suggest that the executive system significantly interacts with the motor learning process, graded by the burden on the executive system.
Active surveillance (AS) (also called "delayed treatment") is becoming recognized as an alternative for many patients with early stage low-grade disease ("low burden" disease).
